Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

This is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who

NRAS
BRAF
platelet count
trametinib
metastatic melanoma
  • 0 views
  • 28 Jul, 2022
  • 1 location
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists

immunomodulator
BRAF
melanoma skin
metastasis
systemic therapy
  • 1231 views
  • 29 Jul, 2022
  • 12 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

131i-mibg
central nervous system tumor
bone marrow procedure
anti-cancer agents
cns neoplasm
  • 1032 views
  • 25 Jul, 2022
  • 106 locations
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

This is a pilot study evaluating the feasibility of using adaptive intermittent dosing of vemurafenib and cobimetinib in BRAF mutant patients with elevated baseline lactate dehydrogenase (LDH

unresectable melanoma
BRAF
serum pregnancy test
cobimetinib
measurable disease
  • 9 views
  • 11 Aug, 2022
  • 1 location
ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

lung carcinoma
platinum-based chemotherapy
BRAF
kidney function test
cancer chemotherapy
  • 0 views
  • 14 Jul, 2022
  • 40 locations
Encorafenib Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma. Dose escalation phase: Previously treated or treatment-nave patients will be evaluated after the

  • 0 views
  • 30 Jan, 2021
  • 1 location
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

An open, multicenter phase II clinical study to evaluate safety and efficacy of HLX208 (BRAF V600E inhibitor) combined with cetuximab for metastatic colorectal cancer (mCRC) with BRAF V600E

  • 0 views
  • 24 Mar, 2022
  • 1 location
  • 0 views
  • 13 Jul, 2022
  • 25 locations
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.

BRAF
adenocarcinoma
cetuximab
folfiri regimen
colorectal adenocarcinoma
  • 7 views
  • 16 Feb, 2022
  • 1 location
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)

class 2 and 3 BRAF mutations.

BRAF
kidney function test
metastasis
measurable disease
liver metastasis
  • 0 views
  • 09 Feb, 2022
  • 1 location